Agenus Inc (AGEN) - Total Assets
Based on the latest financial reports, Agenus Inc (AGEN) holds total assets worth $233.89 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Agenus Inc for net asset value and shareholders' equity analysis.
Agenus Inc - Total Assets Trend (1999–2024)
This chart illustrates how Agenus Inc's total assets have evolved over time, based on quarterly financial data.
Agenus Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Agenus Inc's total assets of $233.89 Million consist of 20.1% current assets and 79.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.9% |
| Accounts Receivable | $407.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.38 Million | 1.5% |
| Goodwill | $24.09 Million | 10.7% |
Asset Composition Trend (1999–2024)
This chart illustrates how Agenus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AGEN market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Agenus Inc's current assets represent 20.1% of total assets in 2024, a decrease from 85.2% in 1999.
- Cash Position: Cash and equivalents constituted 17.9% of total assets in 2024, down from 82.9% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is goodwill at 10.7% of total assets.
Agenus Inc Competitors by Total Assets
Key competitors of Agenus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Agenus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.47 | 0.19 | 0.88 |
| Quick Ratio | 0.47 | 0.19 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-153.18 Million | $-220.49 Million | $-16.10 Million |
Agenus Inc - Advanced Valuation Insights
This section examines the relationship between Agenus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 218.61 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | -27.9% |
| Total Assets | $226.27 Million |
| Market Capitalization | $112.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Agenus Inc's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Agenus Inc's assets decreased by 27.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Agenus Inc (1999–2024)
The table below shows the annual total assets of Agenus Inc from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $226.27 Million | -27.92% |
| 2023-12-31 | $313.91 Million | -24.09% |
| 2022-12-31 | $413.56 Million | -11.25% |
| 2021-12-31 | $465.96 Million | +117.22% |
| 2020-12-31 | $214.51 Million | +38.10% |
| 2019-12-31 | $155.34 Million | +13.88% |
| 2018-12-31 | $136.40 Million | -1.45% |
| 2017-12-31 | $138.40 Million | -11.84% |
| 2016-12-31 | $156.99 Million | -35.19% |
| 2015-12-31 | $242.23 Million | +225.02% |
| 2014-12-31 | $74.53 Million | +113.94% |
| 2013-12-31 | $34.84 Million | +0.47% |
| 2012-12-31 | $34.67 Million | +75.05% |
| 2011-12-31 | $19.81 Million | -35.91% |
| 2010-12-31 | $30.91 Million | -32.63% |
| 2009-12-31 | $45.87 Million | -19.44% |
| 2008-12-31 | $56.95 Million | +27.86% |
| 2007-12-31 | $44.54 Million | -38.95% |
| 2006-12-31 | $72.95 Million | -29.96% |
| 2005-12-31 | $104.15 Million | -21.73% |
| 2004-12-31 | $133.06 Million | -5.01% |
| 2003-12-31 | $140.08 Million | +57.28% |
| 2002-12-31 | $89.06 Million | -4.79% |
| 2001-12-31 | $93.55 Million | -26.90% |
| 2000-12-31 | $127.97 Million | +128.51% |
| 1999-12-31 | $56.00 Million | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a sap… Read more